The Medicines Company (NASDAQ:MDCO) Director Alexander J. Denner bought 431,000 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was bought at an average cost of $33.89 per share, for a total transaction of $14,606,590.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
NASDAQ MDCO traded down $0.43 during trading on Wednesday, reaching $33.25. 1,171,420 shares of the company’s stock were exchanged, compared to its average volume of 1,091,669. The company has a market cap of $2.53 billion, a PE ratio of -11.43 and a beta of 1.36. The Medicines Company has a fifty-two week low of $16.69 and a fifty-two week high of $41.57.
The Medicines (NASDAQ:MDCO) last posted its earnings results on Thursday, April 25th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.09). During the same quarter in the prior year, the business earned ($0.76) earnings per share. The company’s revenue was down 100.0% compared to the same quarter last year. Equities analysts forecast that The Medicines Company will post -2.74 EPS for the current fiscal year.
A number of equities analysts have weighed in on the company. Robert W. Baird assumed coverage on The Medicines in a research report on Wednesday, March 27th. They set an “outperform” rating and a $80.00 price target on the stock. BidaskClub raised The Medicines from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Roth Capital assumed coverage on The Medicines in a research report on Thursday, March 21st. They set a “buy” rating and a $75.00 price target on the stock. Chardan Capital reissued a “buy” rating and set a $90.00 price target (up previously from $85.00) on shares of The Medicines in a research report on Friday, April 26th. Finally, B. Riley set a $38.00 price target on The Medicines and gave the stock a “buy” rating in a research report on Monday. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The Medicines presently has an average rating of “Buy” and an average price target of $62.00.
The Medicines Company Profile
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels.
Featured Article: Beta
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.